Department of Biotechnology and Bioengineering, Kangwon National University, Chuncheon, Gangwon-do 24341, Republic of Korea.
Center for BioMicrosystems, Brain Science Institute, Korea Institute of Science and Technology (KIST), Seoul 02792, Republic of Korea.
Sci Adv. 2020 Jul 31;6(31). doi: 10.1126/sciadv.abc1564. Print 2020 Jul.
The outbreak of the highly contagious and deadly severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as coronavirus disease 2019 (COVID-19), has posed a serious threat to public health across the globe, calling for the development of effective diagnostic markers and therapeutics. Here, we report a highly reliable severity diagnostic biomarker, acetylated 676th lysine transforming growth factor-beta-induced protein (TGFBIp K676Ac). TGFBIp K676Ac was consistently elevated in the blood of patients with SARS-CoV-2 pneumonia ( = 113), especially in patients in the intensive care unit (ICU) compared to non-ICU patients. Patients' blood samples showed increased cytokines and lymphopenia, which are exemplary indicators of SARS-CoV-2 pneumonia. Treatment with TGFBIp neutralizing antibodies suppressed the cytokine storm. The increased level of TGFBIp K676Ac in ICU patients suggests the promise of this protein as a reliable severity diagnostic biomarker for severe SARS-CoV-2 disease.
高度传染性和致命性的严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）的爆发，也称为 2019 年冠状病毒病（COVID-19），对全球公共卫生构成了严重威胁，需要开发有效的诊断标志物和疗法。在这里，我们报告了一种高度可靠的严重程度诊断生物标志物，即乙酰化 676 位赖氨酸转化生长因子-β诱导蛋白（TGFBIp K676Ac）。SARS-CoV-2 肺炎患者的血液中 TGFBIp K676Ac 持续升高（= 113），尤其是与非 ICU 患者相比，ICU 患者中 TGFBIp K676Ac 升高更为明显。患者的血液样本显示细胞因子增加和淋巴细胞减少，这是 SARS-CoV-2 肺炎的典型指标。用 TGFBIp 中和抗体治疗可抑制细胞因子风暴。ICU 患者中 TGFBIp K676Ac 水平升高表明该蛋白作为严重 SARS-CoV-2 疾病可靠严重程度诊断生物标志物的潜力。
